Mylan launches Exemestane tablets in U.S. market following FDA approval

The U.S. Food and Drug Administration recently issued its final approval for Mylan’s Abbreviated New Drug Application (ANDA) for its Exemestane Tablets in a 25mg dosage, which are a generic version of Pfizer’s Aromasin tablets.
The drug, which Mylan has launched in the U.S. market, is used in the treatment of certain types of breast cancer for women are postmenopausal and is the latest addition to Mylan’s extensive collection of oncology treatment drugs. By volume, Mylan is the largest supplier of cancer medication in the U.S.
Exemestane tablets garnered approximately $100 million in sales between February 2016 and the end of January 2017, according to IMS Health. The company has a further 240 pending ANDAs with the FDA that amount to $100.8 billion in annual sales. This include 45 potential first-to-file opportunities worth $39 billion in sales on their own for the year ending Dec. 31, 2016.